AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug's use broadened after a p
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta
There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).